Tumor shrinkage with lanreotide autogel 120 mg as primary therapy in acromegaly: Results of a prospective multicenter clinical trial

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 4, 2014, Pages 1282-1290

  Caron, Philippe J ^a   Bevan, John S ^b   Petersenn, Stephan ^c   Flanagan, Daniel ^d   Tabarin, Antoine ^e   Prévost, Gaëtan ^f   Maisonobe, Pascal ^g   Clermont, Antoine ^g  

^a SERVICE DE PNEUMOLOGIE   (France)

^b ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^c ENDOC Center for Endocrine Tumors   (Germany)

^d DERRIFORD HOSPITAL   (United Kingdom)

^e UNIVERSITÉ DE BORDEAUX   (France)

^f ROUEN UNIVERSITY HOSPITAL   (France)

^g IPSEN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANGIOPEPTIN; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; GROWTH HORMONE; HEMOGLOBIN; HEMOGLOBIN A1C; PROLACTIN; SOMATOMEDIN C;

ACROMEGALY; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; CANCER HORMONE THERAPY; CANCER INHIBITION; CHOLELITHIASIS; CLINICAL TRIAL; DIARRHEA; DIET RESTRICTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FAINTNESS; FEMALE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GROWTH HORMONE SECRETING ADENOMA; HUMAN; INTENTION TO TREAT ANALYSIS; INTRACRANIAL HYPOTENSION; LIQUORRHEA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT;

ACROMEGALY; ADENOMA; ADOLESCENT; ADULT; AGED; FEMALE; GELS; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PEPTIDES, CYCLIC; SOMATOSTATIN; TREATMENT OUTCOME; TUMOR BURDEN; YOUNG ADULT;

EID: 84898423926     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-3318     Document Type: Review

References (23)

1. Katznelson L, Atkinson JL, Cook DM, Ezzat SZ, Hamrahian AH, Miller KK. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly-2011 update. Endocr Pract. 2011;17(suppl 4):1-44.
2. Nomikos P, Buchfelder M, Fahlbusch R. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'. Eur J Endocrinol. 2005;152:379-387.
3. Melmed S, Colao A, Barkan A, et al; Acromegaly Consensus Group. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab. 2009;94:1509-1517.
4. Giustina A, Bronstein MD, Casanueva FF, et al. Current management practices for acromegaly: an international survey. Pituitary. 2011;14:125-133.
5. Colao A, Auriemma RS, Rebora A, et al. Significant tumour shrinkage after 12 months of lanreotide Autogel-120 mg treatment given first-line in acromegaly. Clin Endocrinol (Oxf). 2009;71:237-245.
6. Mercado M, Borges F, Bouterfa H, et al; SMS995B2401 Study Group. A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol (Oxf). 2007;66:859-868.
7. Bevan JS. Clinical review: the antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab. 2005;90: 1856-1863.
8. Resmini E, Dadati P, Ravetti JL, et al. Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting octreotide in an acromegalic patient. J Clin Endocrinol Metab. 2007;92:1592-1599.
9. Giustina A, Mazziotti G, Torri V, Spinello M, Floriani I, Melmed S. Meta-analysis on the effects of octreotide on tumor mass in acromegaly. PLoS One. 2012;7:e36411.
10. Mazziotti G, Giustina A. Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review. Pituitary. 2010;13:60-67.
11. Melmed S, Sternberg R, Cook D, et al. A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab. 2005;90:4405-4410.
12. A'Hern RP. Widening eligibility to phase II trials: constant arcsine difference phase II trials. Control Clin Trials. 2004;25:251-264.
13. American Diabetes Association. Standards of medical care in dia-betes-2013. Diabetes Care. 2013;36 (Suppl 1):S11-S66.
14. Colao A, Ferone D, Marzullo P, et al. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab. 2001;86: 2779-2786.
15. Baldelli R, Colao A, Razzore P, et al. Two-year follow-up of acro-megalic patients treated with slow release lanreotide (30 mg). JClin Endocrinol Metab. 2000;85:4099-4103.
16. Bevan JS, Atkin SL, Atkinson AB, et al. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J Clin En-docrinol Metab. 2002;87:4554-4563.
17. Petersenn S, Schopohl J, Barkan A, et al; Pasireotide Acromegaly Study Group. Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial. JClin Endocrinol Metab. 2010; 95:2781-2789.
18. Colao A, Cappabianca P, Caron P, et al. Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study. Clin Endocrinol (Oxf). 2009;70:757-768.
19. Mazziotti G, Floriani I, Bonadonna S, Torri V, Chanson P, Giustina A. Effects of somatostatin analogs on glucose homeostasis: a meta-analysis of acromegaly studies. JClin Endocrinol Metab. 2009;94: 1500-1508.
20. Chanson P, Borson-Chazot F, KuhnJM, BlumbergJ, Maisonobe P, Delemer B. Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly. Clin Endocrinol (Oxf). 2008;69:299-305.
21. Melmed S, Cook D, Schopohl J, Goth MI, Lam KS, Marek J. Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension. Pituitary. 2010;13:18-28.
22. Bronstein M, Sheppard M, Freda P, et al. Pasireotide LAR is significantly more effective than octreotide LAR at providing biochemical control in patients with acromegaly: results of a 12-month randomized, double-blind, multicenter, phase III study. Endocr Rev. 2012; 33:OR49-3.
23. Bahurel-Barrera H, Assie G, Silvera S, Bertagna X, Coste J, Leg-mann P. Inter-and intra-observer variability in detection and progression assessment with MRI of microadenoma in Cushing's disease patients followed up after bilateral adrenalectomy. Pituitary. 2008;11:263-269.